Trial Profile
Exploratory study of immunologic factors in re-biopsy specimen, peritumoral bronchoalveolar lavage fluid (BALF), and the peripheral blood for predicting response to the third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib on non-small cell lung cancer patients with resistance to the first generation or the second generation EGFR-TKI
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2019
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 20 Sep 2016 New trial record